Contributions of intrinsic mutation rate and selfish selection to levels of de novo HRAS mutations in the paternal germline by Giannoulatou, E. (Eleni) et al.
Contributions of intrinsic mutation rate and selﬁsh
selection to levels of de novo HRAS mutations
in the paternal germline
Eleni Giannoulatoua,1, Gilean McVeanb, Indira B. Taylora, Simon J. McGowana, Geoffrey J. Mahera, Zamin Iqbalb,
Susanne P. Pfeiferb,2, Isaac Turnerb, Emma M. M. Burkitt Wrightc, Jennifer Shortoc, Aysha Itanid, Karen Turnerd,
Lorna Gregoryb, David Buckb, Ewa Rajpert-De Meytse, Leendert H. J. Looijengaf, Bronwyn Kerrc, Andrew O. M. Wilkiea,3,
and Anne Gorielya,1,3
aWeatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, United Kingdom; bWellcome Trust Centre for Human Genetics, University
of Oxford, Oxford OX3 7BN, United Kingdom; cManchester Academic Health Science Centre, University of Manchester, Manchester M13 9WL, United
Kingdom; dInstitute of Reproductive Sciences, Oxford OX4 2HW, United Kingdom; eDepartment of Growth and Reproduction, Copenhagen University
Hospital (Rigshospitalet), DK-2100 Copenhagen, Denmark; and fDepartment of Pathology, Erasmus University Medical Centre, 3000 CA Rotterdam,
The Netherlands
Edited by Arthur L. Beaudet, Baylor College of Medicine, Houston, TX, and approved October 25, 2013 (received for review June 15, 2013)
The RAS proto-oncogene Harvey rat sarcoma viral oncogene ho-
molog (HRAS) encodes a small GTPase that transduces signals from
cell surface receptors to intracellular effectors to control cellular
behavior. Although somatic HRAS mutations have been described
in many cancers, germline mutations cause Costello syndrome
(CS), a congenital disorder associated with predisposition to ma-
lignancy. Based on the epidemiology of CS and the occurrence of
HRAS mutations in spermatocytic seminoma, we proposed that
activating HRAS mutations become enriched in sperm through
a process akin to tumorigenesis, termed selﬁsh spermatogonial
selection. To test this hypothesis, we quantiﬁed the levels, in
blood and sperm samples, of HRAS mutations at the p.G12 codon
and compared the results to changes at the p.A11 codon, at which
activating mutations do not occur. The data strongly support the
role of selection in determining HRAS mutation levels in sperm,
and hence the occurrence of CS, but we also found differences
from themutation pattern in tumorigenesis. First, the relative prev-
alence of mutations in sperm correlates weakly with their in vitro
activating properties and occurrence in cancers. Second, speciﬁc
tandem base substitutions (predominantly GC>TT/AA) occur in
sperm but not in cancers; genomewide analysis showed that this
samemutation is also overrepresented in constitutional pathogenic
and polymorphic variants, suggesting a heightened vulnerability to
these mutations in the germline. We developed a statistical model
to show how both intrinsic mutation rate and selﬁsh selection con-
tribute to the mutational burden borne by the paternal germline.
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Understanding the factors that inﬂuence the apparent rate ofde novo mutations in the genome is central to the study of
genetic diseases and genome diversity. In humans, germline
mutation rates vary by several orders of magnitude, with average
rates of 4–160 × 10−9 per nucleotide for different point muta-
tions (1, 2). Mutations also show a parent-of-origin bias that is
explained by differences in the biology of germ cells in males and
females, with the majority of germline point mutations, small
indels, and nonrecurrent copy number variations showing a strong
paternal bias, believed to originate during the mitotic replications
of spermatogonial stem cells (SSCs) that continue throughout the
reproductive life of the male (3). Direct estimates of germline
mutation rate, based on whole-genome sequencing (WGS) of two-
and three-generation families, concur that among the 30–100
novel point mutations that are acquired in each generation, ∼80%
originate in the paternal germline (4-7). Two recent studies (6, 7)
have further suggested that the major determinant of the total
number of de novo germline point mutations is the age of the
father at conception, increasing by one to two mutations per year.
However, epidemiologically, this rate of increase would be pre-
dicted to result in a modest paternal age effect, with the average
father of a child with a randomly sampled de novo mutation
being ∼2.2 y older than the population average (SI Text).
We and others have proposed that an additional mechanism
promotes the enrichment of de novo pathogenic mutations in the
testes of aging men (8–11). This process, which we term selﬁsh
spermatogonial selection, accounts for the unusual presentation
of a group spontaneous dominant diseases that we collectively
call paternal age effect (PAE) disorders, including Apert syn-
drome, achondroplasia, multiple endocrine neoplasia type 2
(men2b), Costello syndrome (CS), and Noonan syndrome (11).
These disorders occur spontaneously with an apparent birth rate
that is two to three orders of magnitude above the background
rate of mutation (up to 1 in 30,000 for achondroplasia; the es-
timated birth prevalence of CS in the United Kingdom is
∼1:380,000; SI Text), show an extreme paternal bias in origin
(male-to-female ratio of mutation >10:1) and are associated with
Signiﬁcance
Harvey rat sarcoma viral oncogene homolog (HRAS) occupies
an important place in medical history, because it was the ﬁrst
gene in which acquired mutations that led to activation of
a normal protein were associated with cancer, making it the
prototype of the now canonical oncogene mechanism. Here,
we explore what happens when similar HRAS mutations occur
in male germ cells, an issue of practical importance because the
mutations cause a serious congenital disorder, Costello syn-
drome, if transmitted to offspring. We provide evidence that
the mutant germ cells are positively selected, leading to an
increased burden of the mutations as men age. Although there
are many parallels between this germline process and classical
oncogenesis, there are interesting differences of detail, which
are explored in this paper.
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an increase in average paternal age (∼2.5–8.7 y excess), relative
to the general population. Quantiﬁcation of speciﬁc causative
mutations in the FGFR2, FGFR3 (encoding ﬁbroblast growth
factor receptors 2 and 3, respectively), PTPN11, and RET genes
in sperm (8, 10, 12) or whole testes (9, 13–16) led to the proposal
that spermatogonial cells that have acquired rare spontaneous
PAE mutations are positively selected, leading to their pro-
gressive clonal expansion over time (8, 11, 17). Immunohisto-
chemical screening of testicular sections from elderly men
visualizes likely clonal expansion events within the seminiferous
tubules (18).
Supporting the parallels between selﬁsh selection and early
events in tumorigenesis, we reported that strongly activating so-
matic mutations in FGFR3 and Harvey rat sarcoma viral oncogene
homolog (HRAS) occur in spermatocytic seminoma (SpS), a rare
testicular tumor affecting older men that is thought to represent
the extreme outcome of selﬁsh selection. The previous survey (10)
identiﬁed two tumors with FGFR3 c.1948A>G (p.K650E) muta-
tions and ﬁve tumors with HRAS mutations [three samples with
c.182A>G (p.Q61R) and two with c.181C>T (p.Q61K)]. The
ﬁnding of acquired HRAS mutations was noteworthy because
heterozygous germline mutations cause CS, which exhibits the
epidemiological characteristics of a PAE disorder (11, 19, 20).
However, whereas all mutations previously identiﬁed in SpS affect
the p.Q61 codon, 88% of published CS mutations localize to the p.
G12 codon (Fig. 1) and none has been described at p.Q61 (Table
S1). These codons correspond to two of the three hotspots for
mutation in cancer (p.G12, p.G13, and p.Q61), at which missense
substitutions act by locking the RAS molecule in a GTP-bound
conformation, resulting in a constitutively active state (21).
Although HRAS mutations are predicted to be enriched by
selﬁsh selection and have been implicated in SSC growth regu-
lation (22), no study has attempted to document their occurrence
directly in the sperm of healthy males. To explore further the
link between selﬁsh selection and human disease, we quantiﬁed
the levels in blood and sperm of spontaneous mutations around
p.G12 of HRAS, the codon most frequently affected both by
germline CS mutations and by somatically acquired oncogenic
mutations. Our results illustrate both similarities and differences
between selﬁsh selection and classical oncogenic processes.
Results
Oncogenic HRAS p.G12 Codon Mutations Are Elevated in Sperm. To
quantify spontaneous HRAS mutations, we developed a pro-
tocol (Fig. S1) combining restriction enzyme digestion, PCR
ampliﬁcation, massively parallel sequencing, and statistical anal-
ysis (SI Text). Observing that every nonsynonymous single nu-
cleotide substitution at theHRAS p.G12 codon has been described
in cancer and each is associated with a different transforming
activity (23, 24), we selected for mutations by digesting genomic
DNA with the restriction enzyme MspI (cleaves the WT se-
quence 5′-CCGG-3′ at c.32_c.35, irrespective of methylation
status). This strategy allows equal enrichment of all but 1 of 12
possible single-nucleotide substitutions at the MspI site (Fig. 1,
bold) as well as complex mutations. Additional beneﬁts are that
the MspI site includes a CpG dinucleotide, enabling comparison
of transition and transversion rates in the context of both CpG
and non-CpG nucleotides, and encompasses two adjacent
codons, so that mutation levels at the p.G12 CS/cancer hotspot
can be compared with those at p.A11, at which mutations are
anticipated to be selectively neutral. In samples heterozygous for
the SNP rs12628, located 46 bp downstream of c.35G, each
substitution within the MspI site can be phased, allowing us to
establish on which of the two HRAS alleles the original con-
tributing mutational events took place (Fig. 1; SI Text).
To assess the sensitivity and reproducibility of the assay, we
estimated mutation levels in a titration-reconstruction experi-
ment using biological replicates containing 10 μg of control
blood DNA (equivalent to ∼3.3 × 106 copies of the haploid ge-
nome) supplemented with dilution series of genomic DNA from
four CS patients heterozygous for HRAS mutations [range of
input mutant molecules from ∼10 (concentration: 3 × 10−6) to
∼1,000 (concentration: 3 × 10−4)]. To quantify mutation levels,
samples were spiked with ∼100 mutant copies of genomic DNA
from a unique CS patient heterozygous for c.35_36GC>AA
tandem mutation. We found a good correlation between the
amount of input DNA and the mutation levels estimated by
massively parallel sequencing (Fig. 2A). The levels of the
c.34G>A transition were overestimated ∼3.6-fold at the lower
dilution (3 × 10−6), but the c.35_36GC>TT tandem mutation
exhibited lower mutation levels in blood, and a good correlation
between estimates and DNA input was observed down to the 3 ×
10−6 level.
We then used the same strategy to quantify ﬁve single-nucle-
otide substitutions at the p.G12 codon and six substitutions at
p.A11, in 7 blood and 89 sperm samples from healthy donors
(Fig. 2B, Fig. S2A, and Dataset S1). Estimates of mutation levels
from blood varied by mutation, with transitions exhibiting higher
levels than transversions, especially within the c.33_34 CpG di-
nucleotide (Table S2). These levels are likely to reﬂect a combi-
nation of rare endogenous mutations in blood and artifacts
during PCR, as this technique generates ∼2- to 20-fold more
transition than transversion errors (25). Based on these obser-
vations, the results of the titration experiment (Fig. 2A) and the
analysis of skewing with respect to the rs12628 SNP (SI Text and
Fig. S2C), a sample was considered to carry a given substitution
if the measured levels were >3 × 10−6, except for transitions, for
which the calling threshold was set at 10−5. We next analyzed the
levels of individual mutations (relevant statistics and correlation
with donor age are summarized in Table S2). The levels for all
substitutions involving c.32C and c.33C (in p.A11) did not differ
signiﬁcantly between blood and sperm (Fig. 2B and Fig. S2A).
By contrast, the levels at positions c.34G and c.35G (encoding
nonsynonymous changes at p.G12) were frequently higher in
sperm than in blood (Fig. 2B,Middle) and also exhibited positive
correlation with sperm donor age (Fig. 2C and Fig. S2A): in
sperm, the c.34G>A (p.G12S) transition was the most widely
occurring (55/89 samples had levels >10−5) and the most abun-
dant mutation, accounting for 62% of total single-nucleotide
substitutions at codon p.G12. It also showed the strongest posi-
tive correlation with donor age (rs = 0.52). The level of c.35G>A
(p.G12D) (also a transition but not at a CpG) was on average
3.2-fold lower than c.34G>A and was present at >10−5 in 17/89
sperm samples. The three other quantiﬁable single-nucleotide
substitutions at p.G12 are transversions that exhibited lower
c.34G>A  p.G12S (167/58)
c.34G>C  p.G12R (0/12)
c.34G>T  p.G12C (6/25)
c.35G>A  p.G12D (5/50)
c.35G>C  p.G12A (22/8)
c.35G>T  p.G12V (1/253)
c.36C>A  p.G12G (0/0)
c.36C>G  p.G12G (0/0) 
c.36C>T  p.G12G (0/0)
c.32C>A  p.A11D (0/0)
c.32C>G  p.A11G (0/0)
c.32C>T  p.A11V (0/0)
c.33C>A  p.A11A (0/0)
c.33C>G  p.A11A (0/0)
c.33C>T  p.A11A (0/2)
c.37G>A  p.G13S (0/10)
c.37G>C  p.G13R (0/69)
c.37G>T  p.G13C (15/7)
c.38G>A  p.G13D (2/11)
c.38G>C  p.G13A (0/0)
c.38G>T  p.G13V (0/13)
c.39T>A  p.G13G (0/1)
c.39T>C  p.G13G (0/0)
c.39T>G  p.G13G (0/0)
c.31G>A  p.A11T (0/0)
c.31G>C  p.A11P (0/0)
c.31G>T  p.A11S (0/1)
Fig. 1. Genomic context and DNA sequence around the HRAS p.G12 codon.
The relative positions of the p.A11, p.G12, and p.G13 codons to the rs12628
SNP (dashed box) and the MspI restriction sites used for selection (gray
boxes) are indicated. All single-nucleotide substitutions encompassing
p.A11-p.G13 codons and corresponding amino acid changes are indicated,
with those detected by resistance to MspI digestion in bold. The number of
recorded instances of mutation as either a germline (Table S1) or somatic
(COSMIC) change is indicated as (germline/somatic). Note that c.35G>C,
encoding p.G12A, cannot be assayed by MspI digestion as this mutation
creates a new MspI site at position c.35_38.
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background levels and were elevated above 3 × 10−6 in 20/89
samples for c.34G>T (p.G12C), in 18/89 samples for c.35G>T
(p.G12V) and in only 3/89 samples for c.34G>C (p.G12R).
Levels of these transversions were also correlated with donor
age, although more weakly so than for the transitions.
Tandem Base Substitutions Are Overrepresented in the Germline.
Given that our protocol would select any substitution resistant
to MspI digestion, we asked whether multiple nucleotide sub-
stitutions could be identiﬁed. Unexpectedly, 31 independent events
involving dinucleotide substitutions were observed in sperm sam-
ples at levels >3 × 10−6. Aside from c.34G>A;c.36C>T (encoding
p.G12S) and c.34_35GG>TT (p.G12F), each observed in single
sperm samples, all other dinucleotide mutations were tandem
base substitutions (TBS) involving the last two nucleotides of
codon p.G12, comprising c.35_36GC>AA (p.G12E) in 1 sample,
c.35_36GC>AT (p.G12D) in 4 samples, c.35_36GC>TA
(p.G12V) in 3 samples, and c.35_36GC>TT (p.G12V) in 21
samples (Dataset S1, Table S2, and Fig. S2B). Surprisingly, given
that they both encode the same oncogenic p.G12V change and
would therefore be subject to equivalent selection, the average level
of the most prevalent TBS, c.35_36GC > TT, was 1.7-fold higher
than the level of the c.35G>T single-nucleotide substitution.
Levels of this TBS were signiﬁcantly higher in sperm than blood
(P = 0.00002) and correlated strongly (rs = 0.44) with donor age
(Fig. 2C and Table S2).
To assess the implications of the high prevalence of TBS, par-
ticularly GC>TT, we asked whether they could be identiﬁed in
different human genomic datasets (SI Text). We ﬁrst interrogated
the Human Gene Mutation Database (HGMD), in which 441
TBS have been cataloged as pathogenic germline mutations. In
agreement with a recently published study (26), themost numerous
of all 78 possible TBS involve GC>TT (or its reverse complement
GC>AA), representing 14.7%of the total, corresponding to a 10.6-
fold enrichment over a uniform distribution of TBS (P< 10−16; Fig.
3A and Table S3). Of the 64 coding GC>TT/AA, 26 encode
A B
C
D
Fig. 2. Estimation of HRASmutation levels within the c.32_35 MspI site (codons p.A11 and p.G12) in sperm and blood samples. (A) Mutation levels estimated
in a titration-reconstruction experiment with serial dilution of four CS samples mixed with blood carrier DNA and spike DNA. (B) Estimation of mutation levels
for substitutions at p.A11 (Top) and p.G12 (Middle) in 89 sperm (Left) and 7 blood (Right) samples. Color code for each substitution is given on the ﬁgure.
Samples are organized according to their genotype at the rs12628 SNP (TT to the left, CC in the center, and CT heterozygote to the right). The mutation levels
are plotted independently for the two HRAS alleles with respect to the SNP, so that the total mutation level for CT samples is the sum of the counts on each
allele. The age of the sample donor is given at the Bottom. (C) Average levels for mutations at codon p.G12 in sperm samples binned by 5-y age group. (D)
Comparison of levels for different mutations at codon p.G12 in sperm samples (Top) with relative prevalence of mutations reported in CS (Table S1) (Middle)
and in cancer (COSMIC) (Bottom). Correlation between sperm data and other measurements are indicated by Spearman (rs) and Pearson (r) correlation
coefﬁcients with statistical signiﬁcance (NS, not signiﬁcant; *P = 0.02; **P = 0.009; ***P = 0.000004). The color code used in C and D is identical to B.
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changes that (due to the speciﬁcs of the genetic code) can only
arise from a double-nucleotide substitution, including the re-
current RET c.2647_2648GC>TT (p.A883F) mutation associated
with men2B (11, 27).
We next examined the distribution of TBS in cancer. Strik-
ingly, although 406 single-nucleotide substitutions are recorded
at the HRAS p.G12 codon in the Catalogue Of Somatic Muta-
tions in Cancer (COSMIC), there is not a single instance of TBS,
suggesting that a different pattern of mutations (either caused by
distinct mutational mechanisms in somatic and germline cells
and/or speciﬁc mutagen exposure) is observed in these different
cellular contexts. This interpretation is supported by the proﬁle of
3,769 TBS cataloged in COSMIC (Table S3). The most common
TBS in somatic tissues are CC/GG>AA/TT (31.4%) and CC/
GG>TT/AA (19.2%), which represent mutagen-speciﬁc signa-
tures triggered by the action of polycyclic aromatic hydrocarbon
components found in cigarette smoke or UV exposure (28), re-
spectively. By contrast, there were only 107 events (2.8% of TBS)
of GC>TT/AA, indicating that there is a much less marked en-
richment (2.0-fold over random expectation) for this TBS in
cancer (Table S3).
To explore further the impact of TBS, we analyzed the prev-
alence and distribution of TBS contributing to human variation,
based on WGS data (SI Text). We used Cortex, a de novo as-
sembly-based variant calling algorithm (29) to assess TBS rep-
resentation in 85 human genome sequences from the Luhya in
Webuye, Kenya (LWK) dataset of the 1000 Genomes Project
(30) and identiﬁed 5,425,856 nucleotide variants, among which
22,898 (0.42%) involved TBS. Strikingly, the GC>TT/AA change
was the second most common TBS, observed in 1,417 instances
(6.2%), representing a 4.5-fold enrichment (Fig. 3B and Table
S3). Because the pattern of TBS at the HRAS p.G12 codon
suggested that the CpG dinucleotide at position c.36_37 (Fig. 1)
might inﬂuence the apparent c.35_36GC>TT mutation rate, we
further characterized the local sequence context in which the
1,417 genomic GC>TT/AA TBS had occurred. Compared with
the relative frequency of single substitutions (G>T or C>A) in
the same sequence context, the GC>TT/AA TBS is three times
as likely to occur as part of a CpG dinucleotide [842 of 103,732
events (0.81%) for the single substitutions and 35 of 1,417
(2.5%) for TBS; P = 2.2 × 10−8; SI Text]. These genomewide
observations suggest that the sequence context in which the TBS
occurs plays an important, although yet uncharacterized, role,
and in particular we propose that hypermutability of the C>T
transition within the CpG dinucleotide accounts, at least in part,
for the high spontaneous GC>TT/AA mutation rate observed in
the germline.
Comparison Between Prevalence of HRAS Mutations in Sperm and in
CS, SpS, and Cancer Datasets. To establish the biological relevance
of the measurements of HRAS mutation levels in sperm, we
compared these data to the distribution of published CS alleles,
to experimental data generated in our laboratory on mutations
in SpS, and to cancer-associated mutations cataloged in the
COSMIC database.
Of the 236 CS cases reported in the literature, 207 (88%) involve
mutations at codon p.G12 (Fig. 1 and Table S1). The c.34G>A
(p.G12S) mutation, which is associated with a relatively homog-
enous presentation, is by far the most prevalent (81%). Other
p.G12 mutations have also been described, including p.G12A,
p.G12C, p.G12D, p.G12V, and p.G12E. These rarer alleles tend
to be associated with more severe manifestations, often involving
hypertrophic cardiomyopathy and resulting in neonatal mortality
(31–34), consistent with biochemical evidence that p.G12S is less
activating than any other mutation at this codon (23, 24).
We found a strong correlation between the prevalence of
HRAS alleles in sperm and the number of cases reported for each
CS mutation, indicating that the average level of mutation in
sperm is a major determinant of prevalence of different HRAS
alleles in the CS population (Fig. 2D). Comparing the sperm data
with observed births of CS, it is apparent that p.G12S is unex-
pectedly prevalent in CS compared with other p.G12 substitu-
tions, which suggests that these other (more activating) mutations
may be associated with a higher risk of demise during the preg-
nancy (33). In agreement with our ﬁnding that TBS are not un-
common in sperm, a total of six CS patients carrying similar
mutations have been reported (Table S1). Strikingly, among
patients diagnosed with HRAS mutations encoding p.G12V, ﬁve
cases have been associated with TBS (four with c.35_36GC>TT
and one with c.35_36GC>TA), whereas only a single patient car-
ried the c.35G>T substitution (31–33). The predominance of the
c.35_36GC>TT TBS among observed CS alleles supports
the relevance of our sperm data, as this was themajority (21/30) of
the TBS observed.
We extended our previous survey of SpS by screening (SI Text)
a panel of 33 tumors for hotspot mutations in FGFR3 and HRAS
(Table S4). No further FGFR3 mutations were found, but two
additional tumor samples harbored apparently homozygous
HRAS mutations, not observed in matched histologically normal
tissue. The mutations were c.37G>C (p.G13R) and c.182A>G
(p.Q61R) in tumors from men aged 79 and 81 y, respectively
(Fig. S3 A and B). Although these data conﬁrm that HRAS is the
most commonly mutated gene in SpS (11%) and mutation pos-
itivity is strongly correlated with patient age (Fig. S3C), no mu-
tations at codon p.G12 were identiﬁed. Currently, all HRAS
mutations found in SpS are mutually exclusive with CS muta-
tions, which may reﬂect either embryonic or fetal lethality due to
the highly activating nature of the mutations associated with SpS
(35) or the inability of mutant SSC to produce differentiating
meiotic cells and sperm.
As illustrated in Fig. 2D, mutations at the p.G12 codon occur
in different relative proportions in sperm compared with cancers.
In cancers, HRAS p.G12V, which exhibits the lowest GTPase
activity (36) and the highest transformation potential (23), accounts
for 64% of mutations at codon p.G12 (Fig. 1), whereas in sperm,
HRAS p.G12S (c.34G>A) is most abundant, despite its lower
transforming activity. These observations point to a different
mechanism of mutation and/or selection in spermatogonia than
occurs in most tumors, which we investigated further by statis-
tical modeling.
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Fig. 3. Lego plots representing the prevalence of TBS in the human ge-
nome. (A) Data from HGMD. (B) Genomewide variation across 85 LWK whole
genome sequences (Cortex assembler). The x axis represents the original
dinucleotide sequences and their reverse complements, whereas the y axis
indicates the mutated sequence and its reverse complement (the y axis
legend is the same on both plots and to ease visualization, mutated
sequences are shaded in different colors). Plotted on the z axis is the total
number of events for each TBS (Table S3). Owing to the complementary
nature of DNA, only 78 different TBS can occur, and gray areas indicate
changes that do not lead to TBS (such as single-nucleotide substitutions) or
are identical to their reverse complement.
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Modeling Mutation Rate and Selective Advantage. Overall, our ﬁnd-
ings suggest that the HRAS mutation levels in sperm are deter-
mined by an interplay between the intrinsic genomic mutation rate
of a residue and the selective advantage conferred by the resulting
mutant protein on the spermatogonial cell (8, 10, 11). To un-
derstand the relative impact of these two factors in shaping the
outcome of selﬁsh selection, we developed a statistical model (SI
Text). We elaborated a simple model (9) in which from the age of
puberty (13 y), SSC homeostasis is maintained by regular asym-
metrical divisions, i.e., each division generates a daughter sper-
matogonial cell and a differentiating cell that will ultimately
produce sperm. Selﬁsh mutations are predicted to modify the SSC
mitotic behavior, allowing occasional symmetric divisions, leading
to an exponential enrichment of mutations in sperm over time. To
account for the fact that contributing mutations are anticipated to
be rare, we model their occurrence as a Poisson random variable
with parameter μ (i.e., the mutation rate per cell division). We
then deﬁne a selection coefﬁcient parameter (s) that corresponds
to the probability of the occurrence of such symmetric division at
each SSC mitosis. Values of μ and s were then inferred by Monte
Carlo simulation for each HRAS substitution at codons p.A11 and
p.G12 in the 89 sperm samples, with partitioning of the data for
the 46 individuals heterozygous for the rs12628 SNP across the
two alleles.
The model yields signiﬁcantly positive values of s for activating
HRAS mutations at p.G12, whereas for the synonymous or
nonactivating mutations at p.A11, s is close to zero (Fig. 4 and
Table S5). Although s for different mutations at p.G12 reﬂects
their documented in vitro activating properties (lowest for
p.G12S and highest for p.G12V) (23, 24), the narrow range of
values of s, within 1.5-fold, means that the relative abundance of
a given p.G12 mutation is mainly determined by its mutability μ
which varies by a factor sevenfold between c.34G>A (highest;
transition at CpG dinucleotide) and c.35G>T (lowest; trans-
version at non-CpG). The effect of relative mutability is apparent
when examining the distribution of mutations on the two HRAS
alleles in individuals heterozygous for the rs12628 SNP. Whereas
levels of rarer mutations (including TBS) generally exhibit a
marked skewing preference on one or other allele, indicating
that as few as one originating mutation could have contributed to
the ﬁnal levels, this skewing is much less marked for the c.34G>A
transition (p.G12S) because of its higher intrinsic mutation rate
(SI Text and Fig. S2C).
To test further the usefulness of the model, we analyzed three
previously published datasets of mutation levels quantiﬁed in
sperm for substitutions involving FGFR2 c.755C (8, 12), FGFR2
c.758C (12), and FGFR3 c.1948A or c.1949A (10). Although
these datasets were obtained using different methodologies,
estimates of μ for a given category of substitution broadly agreed
both between the datasets and with previously obtained muta-
tion rate estimates (1, 2, 6). Estimates of s and μ for the Apert
c.755C>G mutation originating from two independent datasets
are also in good agreement. Notably, selection coefﬁcients for
the most strongly selected mutations in FGFR2 and FGFR3 are
1.5- to 2.1-fold higher than for the most strongly selected mu-
tation in HRAS, which is likely to account for the lower birth
prevalence of CS (SI Text) compared with the disorders associated
with the speciﬁc FGFR2 and FGFR3 mutations (11) (Table S5).
Discussion
The c.35G>T (p.G12V) substitution in HRAS is of considerable
historical signiﬁcance, because in 1982 it was the ﬁrst missense
change in a proto-oncogene to be implicated in cancer (37, 38).
Three decades later, it is known to be the most frequent onco-
genic mutation in HRAS (COSMIC), but a rare cause of CS
arising through germline mutation (Fig. 1). Here, we have de-
termined the distribution of mutation levels at the p.G12 codon
in sperm and used these observations to model their occurrence
based on intrinsic mutation rate μ and selection coefﬁcient s. We
ﬁnd that although the levels of mutation in sperm are markedly
elevated through a process akin to oncogenesis and are consistent
with a mechanism involving selﬁsh selection, there are also dif-
ferences in the outcome between spermatogenesis and classical
oncogenesis. These variations are likely to reﬂect several underlying
biological processes, including differences in intrinsic mutation rates
and the speciﬁc effects of mutation on proliferation, differentia-
tion, and survival of SSC, acting over many years.
Regarding the primary mutations that fuel the eventual supply
of mutant sperm, the most surprising observation was of multiple
TBS, particularly c.35_36GC>TT, which had an estimated μ
indistinguishable from the c.35G>T transversion encoding the
same amino acid change, p.G12V (Fig. 4). Considerable conﬁ-
dence that these events are real and not experimental artifacts is
provided by the observation of multiple TBS in CS (Table S1).
Although changes in two or more nucleotides arising through
independent mutational events are expected to be extremely rare
(∼10−11) (2), several studies suggest that these events are more
common than expected by chance (26, 39, 40). TBS can either
result from a single concomitant mutational event involving ad-
jacent nucleotides or have arisen through two hits of increasing
selectivity, a mechanism that has been demonstrated in individ-
uals heterozygous for rare FGFR2 mutations (17). In the case of
TBS in sperm at the HRAS p.G12 codon, a mechanism involving
a single concomitant mutational event is suggested by three
observations. First, nearly all complex changes (30/31) involved
bases adjacent to one another within the p.G12 codon (c.34_35
or c.35_36). Second, 28/30 TBS encode amino acid changes that
are also observed as single-nucleotide substitutions (encoding
p.G12V and p.G12D) and among these, 13/28 occurred in sam-
ples that have no detectable levels of the corresponding single-
nucleotide substitution (c.35G>A or c.35G>T). Third, most TBS
(25/30) involved a C>T transition at position c.36 (encoding
a synonymous change as single substitution and not a known
polymorphism); as c.36C is a part of a CpG dinucleotide
(c.36_37), it raises the possibility that hypermutability at this
site could inﬂuence the apparent mutation rate of the adjacent
nucleotide. This proposal is supported by the threefold enrich-
ment of 3′-adjacent guanine nucleotides in the case of GC>TT/
AA TBS in humans, compared with GC>TC SNP. Hypermuta-
bility associated with methylated CpG sequence context has been
described in UV-induced CC>TT dypirimidine changes observed
in sun-exposed skin lesions (28). In nucleotide excision repair-
deﬁcient cells, methylated CpG sequences frequently undergo
Fig. 4. Contributions of mutation rate (μ) and selection (s) to levels in
sperm for mutations in HRAS, FGFR2, and FGFR3. Data for HRAS (this work)
in black; references for data from previous studies are color-coded as red
(8), green (12), and blue (10). Bars and shaded areas represent the 95%
conﬁdence intervals (Table S5).
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CG>TT tandem mutations in response to oxidative DNA damage
(41). Our work highlights a predisposition to speciﬁc TBS that
seems largely restricted to germ cells, and should stimulate
efforts to investigate its biochemical nature.
Our statistical model incorporated a selection parameter s,
deﬁned as the probability of symmetric division at each SSC mi-
tosis. Reassuringly, estimates of s for mutations at the neutral p.
A11 control codon were close to zero, whereas we found positive
values of s for all mutations at the p.G12 codon, consistent with
clonal expansion and selﬁsh selection. Moreover s was highest for
p.G12V (c.35G>T) and lowest for p.G12S (c.34G>A) (Fig. 4 and
Table S5), consistent with their relative in vitro transforming po-
tential (23, 24). Of note, s may encompass a number of biological
processes other than the balance between symmetric and asym-
metric division, including differential survival of cells undergoing
stochastic divisions (42) and cell competition (43). In this context,
survival simply implies the production of mature sperm, so this
could be impaired by several pathologies such as spermatogenic
arrest, senescence, or apoptosis (44). In any case, the net result of
the narrow range of s for different mutations at the p.G12 codon of
HRAS is that μ outweighs s in determining that the most prevalent
mutation, both in sperm and in CS, is c.34G>A (p.G12S).
Finally, it will be of interest to consider the present results
when analyzing de novo mutation load on a genomewide scale.
Although direct estimates of mutation rate based on WGS of
family trios have singled out the importance of paternal age as
the major determinant of the total number of de novo mutations
(6, 7), it is apparent that the vast majority of reported mutations
occur in noncoding parts of the genome and are likely to be
neutral. Therefore, characterization of the inﬂuence of paternal
age, not only on the total mutational load, but speciﬁcally for
different functional classes of mutations, might provide a means
to estimate what fraction of these newly acquired mutations is
likely to be attributable to mechanisms such as selﬁsh selection,
and hence the overall role that this process plays in genome
diversity and disease.
Materials and Methods
Single ejaculates from 89 healthy men (aged 22–74 y) were donated anon-
ymously, and the age of the donor was recorded. Blood samples were
obtained from seven individuals aged 36–71 y. Written informed consent
was obtained from all donors, and samples were collected with the per-
mission of the Oxfordshire Research Ethics Committee (OxREC C03.076). For
SpS analysis, 33 samples were collected from tissue archives. For a detailed
description of the methods, see SI Text.
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